Fibromodulin Reduces Scar Size and Increases Scar Tensile Strength in Normal and Excessive-Mechanical-Loading Porcine Cutaneous Wounds
Penn collection
Degree type
Discipline
Subject
hypertrophic scarring
scarring
tissue regeneration
wound healing
Animals
Cicatrix
Extracellular Matrix Proteins
Fibromodulin
Humans
Injections
Intradermal
Skin
Skin Diseases
Stress
Mechanical
Swine
Tensile Strength
Wound Healing
collagen
fibromodulin
fibromodulin
scleroprotein
animal cell
animal model
animal tissue
Article
confocal laser scanning microscopy
controlled study
cytoarchitecture
histology
mechanical stress
musculoskeletal system parameters
nonhuman
pig
priority journal
scar formation
scar size
scar tensile strength
skin injury
visual analog scale
wound assessment
animal
drug effect
genetics
human
injury
intradermal drug administration
pathology
scar
skin
skin disease
tensile strength
wound healing
Dental Materials
Dentistry
Endodontics and Endodontology
Oral Biology and Oral Pathology
Other Dentistry
Funder
Grant number
License
Copyright date
Distributor
Related resources
Author
Contributor
Abstract
Hypertrophic scarring is a major postoperative complication which leads to severe disfigurement and dysfunction in patients and usually requires multiple surgical revisions due to its high recurrence rates. Excessive-mechanical-loading across wounds is an important initiator of hypertrophic scarring formation. In this study, we demonstrate that intradermal administration of a single extracellular matrix (ECM) molecule—fibromodulin (FMOD) protein—can significantly reduce scar size, increase tensile strength, and improve dermal collagen architecture organization in the normal and even excessive-mechanical-loading red Duroc pig wound models. Since pig skin is recognized by the Food and Drug Administration as the closest animal equivalent to human skin, and because red Duroc pigs show scarring that closely resembles human proliferative scarring and hypertrophic scarring, FMOD-based technologies hold high translational potential and applicability to human patients suffering from scarring—especially hypertrophic scarring. © 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.